Karyopharm Therapeutics Inc. (KPTI) Stake Raised by State Street Corp

State Street Corp increased its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 10.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 511,920 shares of the company’s stock after acquiring an additional 47,127 shares during the quarter. State Street Corp owned 1.09% of Karyopharm Therapeutics worth $4,631,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL acquired a new stake in shares of Karyopharm Therapeutics during the second quarter valued at approximately $136,000. Voya Investment Management LLC raised its holdings in shares of Karyopharm Therapeutics by 42.1% during the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock valued at $136,000 after acquiring an additional 4,444 shares during the period. Trexquant Investment LP acquired a new stake in shares of Karyopharm Therapeutics during the second quarter valued at approximately $202,000. State of Wisconsin Investment Board acquired a new position in Karyopharm Therapeutics in the 2nd quarter valued at approximately $235,000. Finally, ProShare Advisors LLC increased its stake in Karyopharm Therapeutics by 8.0% in the 2nd quarter. ProShare Advisors LLC now owns 27,154 shares of the company’s stock valued at $246,000 after buying an additional 2,021 shares during the period. Institutional investors and hedge funds own 60.92% of the company’s stock.

In other news, SVP Christopher Brett Primiano sold 4,958 shares of the stock in a transaction on Tuesday, November 7th. The shares were sold at an average price of $11.25, for a total transaction of $55,777.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Mansoor Raza Mirza sold 2,882 shares of the stock in a transaction on Friday, September 15th. The stock was sold at an average price of $11.00, for a total transaction of $31,702.00. Following the transaction, the director now owns 2,882 shares in the company, valued at approximately $31,702. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,458 shares of company stock worth $152,778. 14.71% of the stock is currently owned by company insiders.

Several research firms have weighed in on KPTI. ValuEngine lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 31st. Royal Bank Of Canada began coverage on shares of Karyopharm Therapeutics in a research note on Thursday, September 14th. They issued an “outperform” rating and a $14.00 price objective on the stock. BidaskClub upgraded shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 9th. Jefferies Group reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, October 13th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $18.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, September 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $17.33.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) opened at $10.33 on Thursday. Karyopharm Therapeutics Inc. has a 12 month low of $7.48 and a 12 month high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. sell-side analysts anticipate that Karyopharm Therapeutics Inc. will post -2.59 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Karyopharm Therapeutics Inc. (KPTI) Stake Raised by State Street Corp” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.com-unik.info/2017/12/07/karyopharm-therapeutics-inc-kpti-stake-raised-by-state-street-corp.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Want to see what other hedge funds are holding KPTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Karyopharm Therapeutics Inc. (NASDAQ:KPTI).

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

What are top analysts saying about Karyopharm Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Karyopharm Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit